Page 6 - 2020_09-Haematologica-web

haematologica Journal of the Ferrata Storti Foundation
2262 Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study Anders Lindholm Sørensen et al.
Acute Myeloid Leukemia
2273 SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation James Ropa et al.
2286 ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia Jianbiao Zhou et al.
Non-Hodgkin Lymphoma
2298 Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study
Christopher R. Bolen et al.
2308 DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study
Kana Miyazaki et al.
Plasma Cell Disorders
2316 RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS Marcel Seibold et al.
Hemostasis
2327 Thrombin generation in cardiovascular disease and mortality – results from the Gutenberg Health Study Pauline C.S. van Paridon et al.
Coagulation & its Disorders
2335 A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A Toufik Abache et al.
Letters to the Editor
e440 Mortality in children with sickle cell disease in mainland France from 2000 to 2015 Emilie Desselas et al.
http://www.haematologica.org/content/105/9/e440
e444 Circulating cell-free BRAF V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis Lei Cui et al.
http://www.haematologica.org/content/105/9/e444
e448 The long non-coding RNA Cancer Susceptibility 15 (CASC15) is induced by isocitrate dehydrogenase (IDH) mutations and maintains an immature phenotype in adult acute myeloid leukemia
Sarah Grasedieck et al.
http://www.haematologica.org/content/105/9/e448
e454 Transcription factor 4 (TCF4) expression predicts clinical outcome in RUNX1 mutated and translocated acute myeloid leukemia Florentien E. M. in 't Hout et al.
http://www.haematologica.org/content/105/9/e454
e458 Whole exome sequencing identifies mutational signatures of vitreoretinal lymphoma Junwon Lee et al.
http://www.haematologica.org/content/105/9/e458
e461 Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies Thomas Pincez et al.
http://www.haematologica.org/content/105/9/e461
Myeloproliferative Neoplasms
Haematologica 2020; vol. 105 no. 9 - September 2020 http://www.haematologica.org/